Prophylactic HPV vaccines: Underlying mechanisms

Stanley, Margaret, Lowy, Douglas R. and Frazer, Ian (2006) Prophylactic HPV vaccines: Underlying mechanisms. Vaccine, 24 Supplement 3: HPV Vaccines and Screening in the Prevention of Cervical Cancer: S106-S113. doi:10.1016/j.vaccine.2006.05.110


Author Stanley, Margaret
Lowy, Douglas R.
Frazer, Ian
Title Prophylactic HPV vaccines: Underlying mechanisms
Journal name Vaccine   Check publisher's open access policy
ISSN 0264-410X
0264-110X
Publication date 2006-08-21
Year available 2006
Sub-type Article (original research)
DOI 10.1016/j.vaccine.2006.05.110
Open Access Status Not yet assessed
Volume 24
Issue Supplement 3: HPV Vaccines and Screening in the Prevention of Cervical Cancer
Start page S106
End page S113
Total pages 8
Editor F. X. Bosch
J. Cuzick
J. T. Schiller
G. P. Garnett
A. Meheus
E. L. Franco
T. C. Wright
Place of publication Oxford
Publisher Elsevier
Language eng
Subject EX
1108 Medical Microbiology
Abstract Human papillomavirus virus-like particles (HPV VLP) can be generated by the synthesis and self-assembly in vitro of the major virus capsid protein L1. HPV L1 VLPs are morphologically and antigenically almost identical to native virions, and this technology has been exploited to produce HPV L1 VLP subunit vaccines. The vaccines elicit high titres of anti-L I VLP antibodies that persist at levels 10 times that of natural infections for at least 48 months. At present the assumption is that the protection achieved by these vaccines against incident HPV infection and HPV-associated ano-genital pathology is mediated via serum neutralising Immunoglobulin G (IgG). However, since there have been very few vaccine failures thus far, immune correlates of protection have not been established. The available evidence is that the immunodominant neutralising antibodies generated by L1 VLPs are type-specific and are not cross-neutralising, although highly homologous HPV pairs share minor cross-neutralisation epitopes. Important issues remaining to be addressed include the duration of protection and genotype replacement. (c) 2006 Elsevier Ltd. All rights reserved.
Keyword HPV
L1 VLP vaccines
Neutralising antibody
Immune correlates
Genotype replacement
Protection
Epitope mapping
Cross-protection
Q-Index Code EX
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 137 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 137 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 24 Aug 2007, 07:53:06 EST